CVie Therapeutics Company Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$67.5M
- Investors
-
1
CVie Therapeutics Company General Information
Description
Developer of drugs designed to treat cardiovascular diseases. The company's drugs treats hypertension and acute heart failure, enabling customers to get drugs that target the unmet medical needs.
Contact Information
Corporate Office
- 11F., No.36, Songren Rd.
- Xinyi District
- Taipei, 110-73
- Taiwan
Corporate Office
- 11F., No.36, Songren Rd.
- Xinyi District
- Taipei, 110-73
- Taiwan
CVie Therapeutics Company Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 21-Dec-2018 | $67.5M | Completed | Generating Revenue | ||
| 4. Early Stage VC (Series B) | 13-Aug-2013 | Completed | Generating Revenue | |||
| 3. Early Stage VC | Completed | Generating Revenue | ||||
| 2. Early Stage VC (Series A) | 07-Aug-2012 | $6M | $6M | Completed | Generating Revenue | |
| 1. Joint Venture | 07-Aug-2012 | Completed | Generating Revenue |
CVie Therapeutics Company Patents
CVie Therapeutics Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12503484-B2 | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure | Active | 09-Oct-2019 | ||
| US-20230009312-A1 | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure. | Active | 09-Oct-2019 | ||
| JP-2021532190-A | 17 beta-heterocyclic digitalis analogs for the treatment of heart failure | Active | 26-Jul-2018 | ||
| JP-7421815-B2 | 17beta-heterocyclic digitalis analogs for the treatment of heart failure | Active | 26-Jul-2018 | ||
| AU-2019312478-A1 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | Active | 26-Jul-2018 | A61K31/58 |
CVie Therapeutics Company Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDIB Capital Group | Asset Manager | Minority | ||
| China Cardiovascular Focus | Corporation | Minority | ||
| Ivy Blue Holdings | Venture Capital | Minority | ||
| Kleiner Perkins | Venture Capital | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority |
CVie Therapeutics Company FAQs
-
When was CVie Therapeutics Company founded?
CVie Therapeutics Company was founded in 2012.
-
Where is CVie Therapeutics Company headquartered?
CVie Therapeutics Company is headquartered in Taipei, Taiwan.
-
What industry is CVie Therapeutics Company in?
CVie Therapeutics Company’s primary industry is Drug Discovery.
-
Is CVie Therapeutics Company a private or public company?
CVie Therapeutics Company is a Private company.
-
What is the current valuation of CVie Therapeutics Company?
The current valuation of CVie Therapeutics Company is .
-
What is CVie Therapeutics Company’s current revenue?
The current revenue for CVie Therapeutics Company is .
-
How much funding has CVie Therapeutics Company raised over time?
CVie Therapeutics Company has raised $16M.
-
Who are CVie Therapeutics Company’s investors?
CDIB Capital Group, China Cardiovascular Focus, Ivy Blue Holdings, Kleiner Perkins, and LAV (Lilly Asia Fund) are 5 of 6 investors who have invested in CVie Therapeutics Company.
-
When was CVie Therapeutics Company acquired?
CVie Therapeutics Company was acquired on 21-Dec-2018.
-
Who acquired CVie Therapeutics Company?
CVie Therapeutics Company was acquired by Windtree Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process